Objective. To investigate the association between gout and myocardial infarction (MI) in a representative cohort in Taiwan.
Introduction
Coronary artery disease (CAD) comprises a range of diseases from angina pectoris to myocardial infarction (MI); it is a major cause of death around the world and has many well-known risk factors [1, 2] . In CAD, chronic atherosclerosis results in narrowing of the coronary artery and the formation of vulnerable plaques. When these plaques rupture, the formation of thrombi can interrupt coronary blood flow, resulting in MI [3] . Many known risk factors for MI, such as male gender, increasing age, obesity and histories of diabetes mellitus (DM) or hypertension have been supported by epidemiological evidence [4] and are incorporated into risk estimation algorithms [5] .
Gout, one of the most common inflammatory joint diseases, often occurs concurrently with MI risk factors [68] . However, few population-based studies have investigated the effects of gout on the occurrence of MIs [912] . Early evidence reported in the Framingham study found a 60% increased risk for CAD among gout patients [13] . The Health Professional Follow-up study [11] , the Multiple Risk Factor Intervention Trial (MRFIT) [9] and the study based on the British Columbia Linked Health Database [12] reported that patients with gout have a greater risk of MI. However, these studies focused on high-risk or elderly patients. In addition, evidence regarding risks among women with gout is limited.
Therefore, in the current study, we aimed to estimate the incidence of MI among individuals with gout and to determine the magnitude of the association between gout and MI at the population level. In particular, the present study focused on young people and individuals without traditional risk factors.
Patients and methods
This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (approval number 97-1564C) and was conducted in full compliance with relevant local and national ethical and regulatory guidelines.
Study population
This study was conducted in the Taiwanese population because Taiwan has a high incidence and prevalence of gout [14, 15] and has an established National Health Insurance (NHI) database. The NHI system was established in 1995 and requires all residents of Taiwan to participate. As of April 2010, there were 23 074 487 residents enrolled in the system covering >99% of the population. The NHI database contains registration information and data on original claims for reimbursement, including comprehensive information on demographics, dates of clinical visits, diagnostic codes, medical expenditures, family and medical histories and details of prescriptions, examinations and procedures.
The Taiwan National Health Insurance Research Dataset releases sets of sampling files called the Longitudinal Health Insurance Database (LHID), for research purposes. LHID 2000 contains complete original claims data for 1 000 000 beneficiaries randomly sampled from the entire population of NHI beneficiaries in the year 2000. Each individual beneficiary was given a unique serial number. Using linear congruential random number generation, 1 000 000 non-duplicated random numbers were generated. Individuals with serial numbers identical to any of these random numbers were selected. All registration and claims data for these 1 000 000 individuals during the period from 1996 to 2008 were collected and distributed in the LHID 2000. According to the Bureau of NHI, there were no significant differences in age or gender of individuals selected for the LHID and those in the original National Health Insurance Research Dataset. Another analysis from the Bureau of NHI comparing mean insured amounts also found no significant differences. Our primary data source was the LHID, from which we selected all individuals aged >20 years who had no history of MI before the year 2000. Baseline characteristics were defined if an individual met the case definition of each condition before the year 2000.
Case definition of gout
In the present study, the case definition of gout was those who had received a diagnosis of gout [International Classification of Diseases, Ninth Revision (ICD-9) code 274] while seeking medical treatment at either an outpatient or emergency department between 1996 and 1999. Because we use an administrative database, the inability to define gout based on clinical classification criteria [1618] in the present study was primarily because of the lack of clinical detail and laboratory parameters. However, the utility and validity of gout diagnoses in claims databases have been assessed and been shown to be reasonably robust [19, 20] . In addition, our estimate of gout prevalence is similar to that reported in the National Nutrition and Health Survey in Taiwan [21] .
Definition of outcomes
The primary outcome was MI (ICD-9 code 410). We identified patients who had experienced MI by screening the entire database for inpatient claims listing MI as the primary diagnosis. If a patient was hospitalized more than once for MI, only the first episode of MI was used in the analysis. Fatal events were identified by examining discharge status. A validation study found that ICD-9 code 410 identified 89.7% of MI patients in a hospital discharge abstract [22] .
Definition of baseline risk factors for MI
To identify the baseline presence of risk factors for MI, the complete outpatient records database was screened for patients who required two or more treatments for DM (ICD-9 code 250), hypertension (ICD-9 codes 401405), (CHD; ICD-9 codes 411414) or stroke (ICD-9 codes 430438). Because end-stage renal disease (ESRD) requiring renal replacement therapy fulfills the requirement for a catastrophic illness certificate in Taiwan, we identified ESRD patients by linking the LHID to the catastrophic illness registry.
Statistical analysis
Subjects were followed from 1 January 2000 to the date of MI or the end of the study (31 December 2008), whichever came first, and hospitalization rates among individuals with and without gout were compared. Baseline characteristics were compared by t-test for continuous data and logistic regression for categorical variables. An odds ratio (OR) comparing individual with gout and those without gout for categorical baseline characteristics was reported. Differences in MI occurrence between individuals with and without gout were compared using the log-rank test. Cox proportional hazards models were constructed, and the dichotomous variable denoted whether the patient had an MI during the study period. Separate analyses were performed for fatal and non-fatal MI. Covariates used in the models included age, sex and histories of DM, hypertension, CHD, stroke and ESRD occuring between 1996 and 1999. Hazard ratios (HRs) and 95% CIs were computed. A two-sided P < 0.05 was considered statistically significant. All analyses were performed using the statistical software package SPSS, version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
The cohort included 704 503 individuals (men, 360 432; women, 344 071) aged >20 years, who were covered by the NHI system of Taiwan. The mean age of the study population was 42.73 ± 16.6 years, and there was no difference between two genders. Among the study population, 26 556 (3.8%) individuals received a gout diagnosis and treatment sometime between 1996 and 1999. Approximately 70.3% (n = 18 674) of these gout patients were men, and patients who had been diagnosed with gout were significantly older than those who had not been diagnosed with gout (55.4 ± 15.7 vs 42.0 ± 16.3 years, respectively). Table 1 shows the baseline characteristics of individuals with and without gout. Gout patients were significantly more likely to have DM and hypertension, with ORs 4.94 and 7.55, respectively. Gout was also associated with increased ORs for histories of CAD, stroke and ESRD.
The cohort was followed from 1 January 2000 until 31 December 2008, for a total of 5 622 532 person-years, yielding a mean follow-up of 8.0 ± 0.3 years. During this period, 3718 individuals (with gout, n = 463; without gout, n = 3255) were hospitalized because of MI, 299 (with gout, n = 35; without gout, n = 264) of whom suffered a fatal event. The incidence of MI was 2.20 and 0.60 per 1000 person-years among individuals with and without gout, respectively (log-rank test, P < 0.001). As shown in Table 2 , the incidence of both fatal and non-fatal MIs was higher in gout patients (log-rank test, P < 0.001), and this trend was consistent in both men and women.
Next In a total of 599 450 (85.1%) individuals who did not have histories of DM, hypertension, CAD, stroke and ESRD, the risk of MI was still higher in gout patients. During 4 789 787 person-years of follow-up, 1739 subjects were hospitalized because of MIs (patients with gout, n = 112; individuals without gout, n = 1627), which corresponded to an incidence of hospitalization because of MI of 1.1 and 0.3 per 1000 person-years, respectively (log-rank test P < 0.001). Age-and sex-adjusted HRs for the association of gout with all MI were 1.24 (95% CI 1.10, 1.39) and 1.76 (95% CI 1.45, 2.13) for those with and without cardiovascular risk factors, respectively. The significant association was also noted for non-fatal MIs: the age-and sex-adjusted HRs for non-fatal MIs were 1.27 (95% CI 1.12, 1.43) and 1.79 (95% CI 1.47, 2.18) for those with and without cardiovascular risk factors, respectively.
We investigated the association between gout and MI in each age group. As shown in Table 4 , the incidence of MI was higher in individuals with gout than those without in each age group. By comparing individuals without gout in each age group, we found that the difference in MI incidence tended to decrease with advancing age. Among individuals aged >70 years, gout was not independently associated with MI. Gout was not associated with fatal MI in any of the three age groups.
In individuals without cardiovascular risk factors, gout was associated with an increased risk of MI: the age-and sex-adjusted HRs for all MI were 2.03 (95% CI 1.32, 3. 
Discussion
The results of the present study, which were derived from data collected on 26 556 gout patients and 677 947 individuals without gout, showed that the risk for hospitalization because of MI was 23% higher in gout patients than in the non-gout population, after adjustment for age, sex and histories of DM, hypertension, CAD, stroke and ESRD. However, the risk of mortality during the first MI episode was not higher in patients with gout. Therefore the results from our study suggest that proper cardiovascular monitoring should be emphasized for all patients who have been diagnosed with gout. Interestingly, the risk of MI was high in gout patients without cardiovascular risk factors. The reasons for this effect are unclear. One possibility is that gout is an early manifestation of metabolic abnormalities, such as hyperlipidaemia or hyperglycaemia, which are also risk factors for cardiovascular diseases. Another possibility is that the episodic inflammation characteristic of gout promotes the occurrence of MI, particularly among those without other risk factors.
In addition, the risk of MI associated with gout was high across age groups, even in young individuals who were not otherwise at risk of MI. These findings are somewhat contradictory to the theory behind the common practice of treating gout as a simple inflammatory joint disorder and suggest that patients with gout should be closely monitored for cardiovascular diseases, even when they are young and lack traditional cardiovascular risk factors. However, regardless of the mechanism, the independent impact of gout on MI was substantial, and preventive management of cardiovascular diseases is therefore warranted in gout patients, even in the absence of other risk factors.
Other studies also reported that patients with gout are at higher risk of MI. For example, the Health Professional Follow-up study found that 17.8% of patients with gout had a history of CAD, and that the risk of non-fatal MI increased by 59% in patients with gout [11] . Moreover, the MRFIT study revealed that gout was associated with an adjusted OR of 1.26 for MI [9] . De Vera et al. [12] , who used the British Columbia Linked Health Database as their primary database, found a 39% increase in the risk of MI in women with gout who were >65 years of age. The MRFIT study focused on high-risk individuals, i.e. those with a Framingham risk score in the upper 15%, therefore the findings of that study were representative of high-risk individuals. Similarly, De Vera et al. [12] selected patients >65 years, who were presumed to be at a higher risk. In addition to high-risk patients, our study also found an increased risk of MI in gout patients who were young and had no cardiovascular risk factors. These results strongly support the hypothesis that gout has an impact on MI at an early stage. Therefore vigilant monitoring of gout patients for cardiovascular disease symptoms is necessary.
Gender differences have been reported to impact MI risk in gout patients. De Vera et al. reported that women had a higher multivariate relative risk (RR) of MI (RR 1.39) than men (RR 1.11) [12] . However, in our study, the difference between the sexes was narrower, and men were at higher risk of MI (adjusted HRs for all MIs: men 1.33; women 1.21). Only a few studies have reported the impact of gout on cardiovascular diseases in women. In an earlier report we investigated a cohort of gout patients (both men and women) who had undergone health screening. The study revealed that gout was associated with a multivariate adjusted HR for cardiovascular death of 1.97 [23] ; however, we did not perform separate analyses for the two sexes. An earlier Taiwanese study found that the severity of gout attacks was associated with electrocardiographic evidence of MI in both sexes, but this study did not provide data on gender difference [24] . Our recent observations comparing causes of death for 6631 gout patients with those of the national population showed that female gout patients had a slightly higher standardized mortality ratio (men 1.58; women 1.81) for cardiovascular diseases [25] . This heterogeneity regarding sex differences probably reflects variation in the baseline characteristics of the study cohorts. However, we conclude that gout is associated with an increased risk of MI in both women and men.
The risk of fatal MI was not elevated in gout patients in either the present study or that of De Vera et al. [12] . However, several studies [911], including our previous report [23] , noted an elevated risk for cardiovascularrelated death in gout patients. This discrepancy is most likely because of the fact that we collected incident MI events. Therefore mortality not attributable to the first MI event was excluded from the analysis. Because MI events were identified from data on hospital discharge claims, MI-related deaths occurring before hospitalization and sudden deaths not yet diagnosed as MI-related were also not included in the present study. The frequency of sudden cardiac death as the first manifestation of ischaemic heart disease varies, and it was estimated to be as high as 70% in one autopsy study [26] . A recent study estimated that the rate of out-of-hospital sudden death in acute MI sufferers was 35% [27] . In this regard, the magnitude of MI risk, and in particular the risk of fatal MI, in gout patients might be larger than that reported in the present study, and this possibility should be investigated in the future.
The strengths and potential limitations of the present study merit discussion. As a population-based study, the present results can be generalized and are applicable to the general population. The current study represents an analysis of one of the largest reported gout cohorts to date, and the patient source was a representative sample of the general population. Because neither gout nor MI is rare, a 1 in 22 sampling ratio is sufficient to capture all potential cases and events. Because the primary data were claims information from the NHI database, which covers 99.7% of the population in Taiwan, information on exposures, outcomes and covariates was prospectively collected, and missing data or loss to follow-up did not occur. Furthermore, the case definition of gout used in the current study was based on both the www.rheumatology.oxfordjournals.org Gout and myocardial infarction diagnostic code and treatment rather than the diagnostic code alone, which reduced the possibility of misclassification inherent in a claims-based study. However, we did not have information on some potential covariates, such as serum uric acid concentrations, and these could therefore not be included in the modelling process. The use of administrative claims data also precluded adjustment for lifestyle covariates, such as diet and smoking.
In conclusion, the current study demonstrated that gout is an independent risk factor for the occurrence of MI. Gout patients, even those who are relatively young and have no known cardiovascular risk factors, are at a significantly increased risk of MI. Therefore vigilant cardiovascular monitoring of such patients is warranted.
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